John Studeny's Colleagues at Portola Pharmaceuticals Inc
John Studeny's Contact Details
650-246-7000
Portola Pharmaceuticals Inc
John Studeny's Company Details
We are focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, an investigational SYK/JAK inhibitor being developed for the treatment of hematologic cancers. We are continuing to explore new discoveries that impact how serious blood-related disorders are treated and expanding the potential impact of our existing portfolio of medicines.